Clinica Chimica Acta:慢性髓系白血病患者血清伊马替尼及其代谢产物的测定

2019-11-23 gladiator MedSci原创

伊马替尼具有良好的药代动力学特性,但随着时间的推移,初级和次级耐药机制可能导致临床反应的降低。血清伊马替尼浓度与治疗反应呈正相关。

伊马替尼具有良好的药代动力学特性,但随着时间的推移,初级和次级耐药机制可能导致临床反应的降低。血清伊马替尼浓度与治疗反应呈正相关。因此,本研究的目的是建立一种测定伊马替尼及其活性代谢物n -去甲基伊马替尼的方法。

采用液相色谱-串联质谱法(LC-MS/MS)测定血清伊马替尼和N-desmethyl imatinib水平,并根据CLSI (The Clinical & Laboratory Standards Institute)协议进行验证研究。收集40例慢性髓系白血病(CML)患者血清,采用LC-MS/MS和超高效液相色谱(UHPLC)方法进行分析。

LC-MS / MS方法的线性范围和相关系数分别为12.2–12,500 ng / mL0.9987 定量限为24.4μng/ mL 伊马替尼和N-去甲基伊马替尼的保留时间分别为1.661.60 min 两种方法的结果之间没有统计学上的差异。

这种LC-MS/MS方法具有成本效益和优点,如使用低血清量,仅需要简单的预处理步骤(仅蛋白沉淀)和分析的周转时间减少。

原始出处:

Duygu Eryavuz OnmazSedat AbusogluDetermination of serum imatinib and its' metabolite in patients chronic myeloid leukemia

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

 

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1849798, encodeId=eee81849e98b2, content=<a href='/topic/show?id=61815385aa' target=_blank style='color:#2F92EE;'>#CTA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5385, encryptionId=61815385aa, topicName=CTA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec9955, createdName=windight, createdTime=Sun Jul 12 18:23:00 CST 2020, time=2020-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1662309, encodeId=19d6166230960, content=<a href='/topic/show?id=6a426545472' target=_blank style='color:#2F92EE;'>#测定#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65454, encryptionId=6a426545472, topicName=测定)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8db925396819, createdName=丁鹏鹏, createdTime=Mon Dec 30 08:23:00 CST 2019, time=2019-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1822097, encodeId=55c3182209eff, content=<a href='/topic/show?id=ee4b1021266e' target=_blank style='color:#2F92EE;'>#髓系白血病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102126, encryptionId=ee4b1021266e, topicName=髓系白血病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b79433, createdName=fangcong, createdTime=Tue Apr 21 04:23:00 CST 2020, time=2020-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1428598, encodeId=b726142859872, content=<a href='/topic/show?id=5d3d53e27bd' target=_blank style='color:#2F92EE;'>#慢性髓系白血病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53727, encryptionId=5d3d53e27bd, topicName=慢性髓系白血病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ba484099594, createdName=jmtang, createdTime=Mon Nov 25 12:23:00 CST 2019, time=2019-11-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1513463, encodeId=098d151346326, content=<a href='/topic/show?id=8e4b2540671' target=_blank style='color:#2F92EE;'>#代谢产物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25406, encryptionId=8e4b2540671, topicName=代谢产物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2e1510553828, createdName=124987c6m39暂无昵称, createdTime=Mon Nov 25 12:23:00 CST 2019, time=2019-11-25, status=1, ipAttribution=)]
    2020-07-12 windight
  2. [GetPortalCommentsPageByObjectIdResponse(id=1849798, encodeId=eee81849e98b2, content=<a href='/topic/show?id=61815385aa' target=_blank style='color:#2F92EE;'>#CTA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5385, encryptionId=61815385aa, topicName=CTA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec9955, createdName=windight, createdTime=Sun Jul 12 18:23:00 CST 2020, time=2020-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1662309, encodeId=19d6166230960, content=<a href='/topic/show?id=6a426545472' target=_blank style='color:#2F92EE;'>#测定#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65454, encryptionId=6a426545472, topicName=测定)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8db925396819, createdName=丁鹏鹏, createdTime=Mon Dec 30 08:23:00 CST 2019, time=2019-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1822097, encodeId=55c3182209eff, content=<a href='/topic/show?id=ee4b1021266e' target=_blank style='color:#2F92EE;'>#髓系白血病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102126, encryptionId=ee4b1021266e, topicName=髓系白血病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b79433, createdName=fangcong, createdTime=Tue Apr 21 04:23:00 CST 2020, time=2020-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1428598, encodeId=b726142859872, content=<a href='/topic/show?id=5d3d53e27bd' target=_blank style='color:#2F92EE;'>#慢性髓系白血病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53727, encryptionId=5d3d53e27bd, topicName=慢性髓系白血病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ba484099594, createdName=jmtang, createdTime=Mon Nov 25 12:23:00 CST 2019, time=2019-11-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1513463, encodeId=098d151346326, content=<a href='/topic/show?id=8e4b2540671' target=_blank style='color:#2F92EE;'>#代谢产物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25406, encryptionId=8e4b2540671, topicName=代谢产物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2e1510553828, createdName=124987c6m39暂无昵称, createdTime=Mon Nov 25 12:23:00 CST 2019, time=2019-11-25, status=1, ipAttribution=)]
    2019-12-30 丁鹏鹏
  3. [GetPortalCommentsPageByObjectIdResponse(id=1849798, encodeId=eee81849e98b2, content=<a href='/topic/show?id=61815385aa' target=_blank style='color:#2F92EE;'>#CTA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5385, encryptionId=61815385aa, topicName=CTA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec9955, createdName=windight, createdTime=Sun Jul 12 18:23:00 CST 2020, time=2020-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1662309, encodeId=19d6166230960, content=<a href='/topic/show?id=6a426545472' target=_blank style='color:#2F92EE;'>#测定#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65454, encryptionId=6a426545472, topicName=测定)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8db925396819, createdName=丁鹏鹏, createdTime=Mon Dec 30 08:23:00 CST 2019, time=2019-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1822097, encodeId=55c3182209eff, content=<a href='/topic/show?id=ee4b1021266e' target=_blank style='color:#2F92EE;'>#髓系白血病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102126, encryptionId=ee4b1021266e, topicName=髓系白血病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b79433, createdName=fangcong, createdTime=Tue Apr 21 04:23:00 CST 2020, time=2020-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1428598, encodeId=b726142859872, content=<a href='/topic/show?id=5d3d53e27bd' target=_blank style='color:#2F92EE;'>#慢性髓系白血病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53727, encryptionId=5d3d53e27bd, topicName=慢性髓系白血病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ba484099594, createdName=jmtang, createdTime=Mon Nov 25 12:23:00 CST 2019, time=2019-11-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1513463, encodeId=098d151346326, content=<a href='/topic/show?id=8e4b2540671' target=_blank style='color:#2F92EE;'>#代谢产物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25406, encryptionId=8e4b2540671, topicName=代谢产物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2e1510553828, createdName=124987c6m39暂无昵称, createdTime=Mon Nov 25 12:23:00 CST 2019, time=2019-11-25, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1849798, encodeId=eee81849e98b2, content=<a href='/topic/show?id=61815385aa' target=_blank style='color:#2F92EE;'>#CTA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5385, encryptionId=61815385aa, topicName=CTA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec9955, createdName=windight, createdTime=Sun Jul 12 18:23:00 CST 2020, time=2020-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1662309, encodeId=19d6166230960, content=<a href='/topic/show?id=6a426545472' target=_blank style='color:#2F92EE;'>#测定#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65454, encryptionId=6a426545472, topicName=测定)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8db925396819, createdName=丁鹏鹏, createdTime=Mon Dec 30 08:23:00 CST 2019, time=2019-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1822097, encodeId=55c3182209eff, content=<a href='/topic/show?id=ee4b1021266e' target=_blank style='color:#2F92EE;'>#髓系白血病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102126, encryptionId=ee4b1021266e, topicName=髓系白血病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b79433, createdName=fangcong, createdTime=Tue Apr 21 04:23:00 CST 2020, time=2020-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1428598, encodeId=b726142859872, content=<a href='/topic/show?id=5d3d53e27bd' target=_blank style='color:#2F92EE;'>#慢性髓系白血病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53727, encryptionId=5d3d53e27bd, topicName=慢性髓系白血病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ba484099594, createdName=jmtang, createdTime=Mon Nov 25 12:23:00 CST 2019, time=2019-11-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1513463, encodeId=098d151346326, content=<a href='/topic/show?id=8e4b2540671' target=_blank style='color:#2F92EE;'>#代谢产物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25406, encryptionId=8e4b2540671, topicName=代谢产物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2e1510553828, createdName=124987c6m39暂无昵称, createdTime=Mon Nov 25 12:23:00 CST 2019, time=2019-11-25, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1849798, encodeId=eee81849e98b2, content=<a href='/topic/show?id=61815385aa' target=_blank style='color:#2F92EE;'>#CTA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5385, encryptionId=61815385aa, topicName=CTA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec9955, createdName=windight, createdTime=Sun Jul 12 18:23:00 CST 2020, time=2020-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1662309, encodeId=19d6166230960, content=<a href='/topic/show?id=6a426545472' target=_blank style='color:#2F92EE;'>#测定#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65454, encryptionId=6a426545472, topicName=测定)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8db925396819, createdName=丁鹏鹏, createdTime=Mon Dec 30 08:23:00 CST 2019, time=2019-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1822097, encodeId=55c3182209eff, content=<a href='/topic/show?id=ee4b1021266e' target=_blank style='color:#2F92EE;'>#髓系白血病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102126, encryptionId=ee4b1021266e, topicName=髓系白血病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b79433, createdName=fangcong, createdTime=Tue Apr 21 04:23:00 CST 2020, time=2020-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1428598, encodeId=b726142859872, content=<a href='/topic/show?id=5d3d53e27bd' target=_blank style='color:#2F92EE;'>#慢性髓系白血病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53727, encryptionId=5d3d53e27bd, topicName=慢性髓系白血病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ba484099594, createdName=jmtang, createdTime=Mon Nov 25 12:23:00 CST 2019, time=2019-11-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1513463, encodeId=098d151346326, content=<a href='/topic/show?id=8e4b2540671' target=_blank style='color:#2F92EE;'>#代谢产物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25406, encryptionId=8e4b2540671, topicName=代谢产物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2e1510553828, createdName=124987c6m39暂无昵称, createdTime=Mon Nov 25 12:23:00 CST 2019, time=2019-11-25, status=1, ipAttribution=)]